Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Excipients must be carefully chosen to ensure optimum protection for vaccines and live biotherapeutic products.

CARBOGEN AMCIS has announced significant investments to increase manufacturing capacity in Switzerland and France.

CordenPharma added a 3000-L solid-phase peptide synthesis vessel to its GMP API facility in Boulder, CO.

RNA is easier to manipulate than DNA but challenging to deliver to the right cells.

Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks? 

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.

Synthetic biology can help researchers circumvent the challenges of traditional methods of antibody generation.

Roche will apply ProBioGen’s proprietary GlymaxX technology to boost the antibody-dependent cellular cytotoxicity activity of antibodies.